David Paul Becker
CIK 1332082 · Chief Financial Officer · last filed 2012-12-14
David Paul Becker is a Chief Financial Officer who has filed 6 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for PTX, was dated Dec 14, 2012. Across all open-market trades the lifetime net is −$618.9K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARXT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CHESTER, NJ 07930
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Chief Financial Officer | 20,000 | — | — | $0 | 2 | 2012-12-14 |
| MiddleBrook Pharmaceuticals, Inc. (MBRK) Delisted | EVP & CFO | — | — | — | $0 | 1 | 2008-09-09 |
| Adams Respiratory Therapeutics, Inc. (ARXT) Delisted | CF & AO | 4,904 | — | — | -$618.9K | 3 | 2007-01-30 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-12-14 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Mixed | +200,000 | $0 | EDGAR |
| 2011-12-06 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-09-09 | MiddleBrook Pharmaceuticals, Inc. (MBRK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-01-30 | Adams Respiratory Therapeutics, Inc. (ARXT) Delisted | Sell (S) | −5,054 | -$226.1K | EDGAR |
| 2007-01-30 | Adams Respiratory Therapeutics, Inc. (ARXT) Delisted | Mixed | +5,054 | -$303.8K | EDGAR |
| 2007-01-05 | Adams Respiratory Therapeutics, Inc. (ARXT) Delisted | Mixed | — | -$70.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).